Investment Summary

Ampersand Capital Partners Invests In Syft

On April 18, 2022, growth capital firm Ampersand Capital Partners invested in test/measurement equipment company Syft

Investment Highlights
  • This is Ampersand Capital Partners’ 2nd transaction in the Test/Measurement Equipment sector.
  • This is Ampersand Capital Partners’ 2nd transaction in New Zealand.

Investment Summary
Date 2022-04-18
Target Syft
Sector Test/Measurement Equipment
Investor(s) Ampersand Capital Partners
Deal Type Growth Capital

Target

Syft

Christchurch , New Zealand
website
Syft develops SIFT-MS, a form of direct mass spectrometry that analyses volatile organic compounds (VOCs) in the air with typical detection limits at parts-per-trillion level (by volume; pptv). Syft was founded in 2002 and is based in Christchurch, New Zealand.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

website

Category Growth Capital Firm
Founded 1988
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 68 of 79
Sector (Test/Measurement Equipment) 2 of 2
Type (Growth Capital) 22 of 26
Country (New Zealand) 2 of 2
Year (2022) 3 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-17 vivitide

Gardner, Massachusetts, United States

vivitide is a provider of custom peptide synthesis services, custom antibodies, catalog peptides, and biochemicals to academia, pharmaceutical, biotech, and diagnostic companies worldwide. vivitide was founded in 1998 and is based in Gardner, Massachusetts.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-02 Vernal Biosciences

Colchester, Vermont, United States

Vernal Biosciences provides mRNA and LNP-mRNA manufacturing services to democratize the use of mRNA for all use cases ranging from drug discovery to clinical development across all use cases such as gene editing and regulation, cellular programming, vaccines, mRNA replacement, oncology, autoimmune, and protein degradation. Vernal Biosciences is based in Colchester, Vermont.

Buy -
Mergr

Product

Company

Legal